September 9th, 2024

Americans pay eight times more for hearing aids than the British

The U.S. hearing aid market is dominated by six firms, resulting in high prices. Recent FDA regulations may increase competition, but the cartel's strategies and political influence complicate market entry.

Read original articleLink Icon
Americans pay eight times more for hearing aids than the British

The hearing aid industry in the U.S. is characterized by high prices and limited competition, largely due to a cartel of six major firms that control the market. Americans pay significantly more for hearing aids compared to other countries, with the average cost reaching $4,700 per pair. This high cost is attributed to a combination of factors, including the requirement for prescriptions, which restricts access to cheaper alternatives. Despite the prevalence of hearing loss among older adults, only 20% use hearing aids, often due to affordability issues. Recent regulatory changes by the FDA, prompted by the Biden administration, aim to allow over-the-counter sales of hearing aids, potentially increasing competition and lowering prices. However, the cartel employs various strategies to maintain its dominance, including patent pools and vertical integration, which complicate market entry for new competitors. The firms also exert significant political influence through lobbying and campaign contributions, further entrenching their market position. While the new FDA rules are a step towards reducing costs, the effectiveness of these changes remains uncertain, as the cartel's established practices may continue to hinder competition.

- The U.S. hearing aid market is dominated by a cartel of six firms, leading to high prices.

- Recent FDA regulations allow over-the-counter sales of hearing aids, aiming to increase competition.

- The average cost of hearing aids in the U.S. is significantly higher than in other countries.

- The cartel uses patents and vertical integration to maintain market control.

- Political lobbying and campaign contributions play a crucial role in sustaining the cartel's influence.

Related

The Opaque Industry Inflating Prices for Prescription Drugs

The Opaque Industry Inflating Prices for Prescription Drugs

Pharmacy Benefit Managers (PBMs) like CVS Health, Cigna, and UnitedHealth Group are criticized for increasing prescription drug costs in the US. Despite claims of cost reduction, PBMs allegedly steer towards expensive drugs, charge high markups, and prioritize financial gains over patients. Lawmakers are scrutinizing their practices for potential price inflation and anticompetitive behavior.

Middlemen have outsized influence on drug prices due to market consolidation,FTC

Middlemen have outsized influence on drug prices due to market consolidation,FTC

The FTC highlights PBMs' dominance in U.S. drug pricing. Top PBMs control 79% of claims, raising concerns about cost inflation, lack of transparency, and conflicts of interest. Regulation and scrutiny are needed.

The Mafia of Pharma Pricing

The Mafia of Pharma Pricing

The Federal Trade Commission report exposes health care conglomerates, particularly pharmacy benefit managers (PBMs), for inflating drug prices and manipulating the market. PBMs' practices contribute to rising healthcare costs and may lead to potential lawsuits.

AirPods Pro 2 adds 'clinical grade' hearing aid feature

AirPods Pro 2 adds 'clinical grade' hearing aid feature

Apple will introduce new hearing health features for AirPods Pro 2, including a clinical-grade hearing aid mode and a hearing protection mode, pending regulatory approval and available in over 100 countries.

Joe Biden Engineered Apple's New AirPods

Joe Biden Engineered Apple's New AirPods

Apple's AirPods Pro 2 will function as FDA-approved hearing aids, allowing users to customize sound settings through a hearing test in the Apple Health app, enhancing accessibility and affordability.

Link Icon 1 comments